Overview
MindMed is a clinical-stage psychedelic medicine company developing novel therapeutics derived from LSD, MDMA, and ibogaine analogs for neurological and psychiatric disorders. Their lead asset MM120 (LSD tartrate) has shown promising Phase 2b results for generalized anxiety disorder.
More in Psychedelics
Latest industry news
Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Target Brain Health
2026-07-11 · Funding
BrainCo Pushes to Commercialize Brain-Tech as China's BCI Ambitions Come Into Focus
2026-07-10 · Industry
FDA Clears PoNS Device for Stroke Rehabilitation, Broadening Neurostimulation's Clinical Reach
2026-07-09 · Policy
Neurovalens Wins FDA Approval for PTSD Therapy Targeting US Veterans
2026-07-08 · Policy
Company details
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →